Global Varicella Attenuated Live Vaccine Market Insights and Forecast to 2031

Report ID: 1228804 | Published Date: Jan 2025 | No. of Page: 97 | Base Year: 2024 | Rating: 4.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Varicella Attenuated Live Vaccine Product Introduction
    1.2 Market by Type
        1.2.1 Global Varicella Attenuated Live Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Monovalent Vaccine
        1.2.3 Combination Vaccine
    1.3 Market by Application
        1.3.1 Global Varicella Attenuated Live Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Kids Injection
        1.3.3 Adults Injection
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Varicella Attenuated Live Vaccine Sales Estimates and Forecasts 2017-2028
    2.2 Global Varicella Attenuated Live Vaccine Revenue Estimates and Forecasts 2017-2028
    2.3 Global Varicella Attenuated Live Vaccine Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Varicella Attenuated Live Vaccine Sales by Region
        2.4.1 Global Varicella Attenuated Live Vaccine Sales by Region (2017-2022)
        2.4.2 Global Sales Varicella Attenuated Live Vaccine by Region (2023-2028)
    2.5 Global Varicella Attenuated Live Vaccine Revenue by Region
        2.5.1 Global Varicella Attenuated Live Vaccine Revenue by Region (2017-2022)
        2.5.2 Global Varicella Attenuated Live Vaccine Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Varicella Attenuated Live Vaccine Sales by Manufacturers
        3.1.1 Global Top Varicella Attenuated Live Vaccine Manufacturers by Sales (2017-2022)
        3.1.2 Global Varicella Attenuated Live Vaccine Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Varicella Attenuated Live Vaccine in 2021
    3.2 Global Varicella Attenuated Live Vaccine Revenue by Manufacturers
        3.2.1 Global Varicella Attenuated Live Vaccine Revenue by Manufacturers (2017-2022)
        3.2.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Varicella Attenuated Live Vaccine Revenue in 2021
    3.3 Global Varicella Attenuated Live Vaccine Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Varicella Attenuated Live Vaccine Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Varicella Attenuated Live Vaccine Sales by Type
        4.1.1 Global Varicella Attenuated Live Vaccine Historical Sales by Type (2017-2022)
        4.1.2 Global Varicella Attenuated Live Vaccine Forecasted Sales by Type (2023-2028)
        4.1.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2017-2028)
    4.2 Global Varicella Attenuated Live Vaccine Revenue by Type
        4.2.1 Global Varicella Attenuated Live Vaccine Historical Revenue by Type (2017-2022)
        4.2.2 Global Varicella Attenuated Live Vaccine Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2017-2028)
    4.3 Global Varicella Attenuated Live Vaccine Price by Type
        4.3.1 Global Varicella Attenuated Live Vaccine Price by Type (2017-2022)
        4.3.2 Global Varicella Attenuated Live Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Varicella Attenuated Live Vaccine Sales by Application
        5.1.1 Global Varicella Attenuated Live Vaccine Historical Sales by Application (2017-2022)
        5.1.2 Global Varicella Attenuated Live Vaccine Forecasted Sales by Application (2023-2028)
        5.1.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2017-2028)
    5.2 Global Varicella Attenuated Live Vaccine Revenue by Application
        5.2.1 Global Varicella Attenuated Live Vaccine Historical Revenue by Application (2017-2022)
        5.2.2 Global Varicella Attenuated Live Vaccine Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2017-2028)
    5.3 Global Varicella Attenuated Live Vaccine Price by Application
        5.3.1 Global Varicella Attenuated Live Vaccine Price by Application (2017-2022)
        5.3.2 Global Varicella Attenuated Live Vaccine Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Varicella Attenuated Live Vaccine Market Size by Type
        6.1.1 North America Varicella Attenuated Live Vaccine Sales by Type (2017-2028)
        6.1.2 North America Varicella Attenuated Live Vaccine Revenue by Type (2017-2028)
    6.2 North America Varicella Attenuated Live Vaccine Market Size by Application
        6.2.1 North America Varicella Attenuated Live Vaccine Sales by Application (2017-2028)
        6.2.2 North America Varicella Attenuated Live Vaccine Revenue by Application (2017-2028)
    6.3 North America Varicella Attenuated Live Vaccine Market Size by Country
        6.3.1 North America Varicella Attenuated Live Vaccine Sales by Country (2017-2028)
        6.3.2 North America Varicella Attenuated Live Vaccine Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Varicella Attenuated Live Vaccine Market Size by Type
        7.1.1 Europe Varicella Attenuated Live Vaccine Sales by Type (2017-2028)
        7.1.2 Europe Varicella Attenuated Live Vaccine Revenue by Type (2017-2028)
    7.2 Europe Varicella Attenuated Live Vaccine Market Size by Application
        7.2.1 Europe Varicella Attenuated Live Vaccine Sales by Application (2017-2028)
        7.2.2 Europe Varicella Attenuated Live Vaccine Revenue by Application (2017-2028)
    7.3 Europe Varicella Attenuated Live Vaccine Market Size by Country
        7.3.1 Europe Varicella Attenuated Live Vaccine Sales by Country (2017-2028)
        7.3.2 Europe Varicella Attenuated Live Vaccine Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Varicella Attenuated Live Vaccine Market Size by Type
        8.1.1 Asia Pacific Varicella Attenuated Live Vaccine Sales by Type (2017-2028)
        8.1.2 Asia Pacific Varicella Attenuated Live Vaccine Revenue by Type (2017-2028)
    8.2 Asia Pacific Varicella Attenuated Live Vaccine Market Size by Application
        8.2.1 Asia Pacific Varicella Attenuated Live Vaccine Sales by Application (2017-2028)
        8.2.2 Asia Pacific Varicella Attenuated Live Vaccine Revenue by Application (2017-2028)
    8.3 Asia Pacific Varicella Attenuated Live Vaccine Market Size by Region
        8.3.1 Asia Pacific Varicella Attenuated Live Vaccine Sales by Region (2017-2028)
        8.3.2 Asia Pacific Varicella Attenuated Live Vaccine Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Varicella Attenuated Live Vaccine Market Size by Type
        9.1.1 Latin America Varicella Attenuated Live Vaccine Sales by Type (2017-2028)
        9.1.2 Latin America Varicella Attenuated Live Vaccine Revenue by Type (2017-2028)
    9.2 Latin America Varicella Attenuated Live Vaccine Market Size by Application
        9.2.1 Latin America Varicella Attenuated Live Vaccine Sales by Application (2017-2028)
        9.2.2 Latin America Varicella Attenuated Live Vaccine Revenue by Application (2017-2028)
    9.3 Latin America Varicella Attenuated Live Vaccine Market Size by Country
        9.3.1 Latin America Varicella Attenuated Live Vaccine Sales by Country (2017-2028)
        9.3.2 Latin America Varicella Attenuated Live Vaccine Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Varicella Attenuated Live Vaccine Market Size by Type
        10.1.1 Middle East and Africa Varicella Attenuated Live Vaccine Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Type (2017-2028)
    10.2 Middle East and Africa Varicella Attenuated Live Vaccine Market Size by Application
        10.2.1 Middle East and Africa Varicella Attenuated Live Vaccine Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Application (2017-2028)
    10.3 Middle East and Africa Varicella Attenuated Live Vaccine Market Size by Country
        10.3.1 Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Merck
        11.1.1 Merck Corporation Information
        11.1.2 Merck Overview
        11.1.3 Merck Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Merck Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Merck Recent Developments
    11.2 BCHT
        11.2.1 BCHT Corporation Information
        11.2.2 BCHT Overview
        11.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 BCHT Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 BCHT Recent Developments
    11.3 Shanghai Institute
        11.3.1 Shanghai Institute Corporation Information
        11.3.2 Shanghai Institute Overview
        11.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Shanghai Institute Recent Developments
    11.4 GSK
        11.4.1 GSK Corporation Information
        11.4.2 GSK Overview
        11.4.3 GSK Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 GSK Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 GSK Recent Developments
    11.5 Keygen
        11.5.1 Keygen Corporation Information
        11.5.2 Keygen Overview
        11.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Keygen Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Keygen Recent Developments
    11.6 Green Cross
        11.6.1 Green Cross Corporation Information
        11.6.2 Green Cross Overview
        11.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Green Cross Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Green Cross Recent Developments
    11.7 Biken
        11.7.1 Biken Corporation Information
        11.7.2 Biken Overview
        11.7.3 Biken Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Biken Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Biken Recent Developments
    11.8 Shanghai Rongsheng Biotech
        11.8.1 Shanghai Rongsheng Biotech Corporation Information
        11.8.2 Shanghai Rongsheng Biotech Overview
        11.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Shanghai Rongsheng Biotech Recent Developments
    11.9 Changchun Changsheng Life Sciences Limited
        11.9.1 Changchun Changsheng Life Sciences Limited Corporation Information
        11.9.2 Changchun Changsheng Life Sciences Limited Overview
        11.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Changchun Changsheng Life Sciences Limited Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Varicella Attenuated Live Vaccine Industry Chain Analysis
    12.2 Varicella Attenuated Live Vaccine Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Varicella Attenuated Live Vaccine Production Mode & Process
    12.4 Varicella Attenuated Live Vaccine Sales and Marketing
        12.4.1 Varicella Attenuated Live Vaccine Sales Channels
        12.4.2 Varicella Attenuated Live Vaccine Distributors
    12.5 Varicella Attenuated Live Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Varicella Attenuated Live Vaccine Industry Trends
    13.2 Varicella Attenuated Live Vaccine Market Drivers
    13.3 Varicella Attenuated Live Vaccine Market Challenges
    13.4 Varicella Attenuated Live Vaccine Market Restraints
14 Key Findings in The Global Varicella Attenuated Live Vaccine Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
List of Tables
    Table 1. Global Varicella Attenuated Live Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Monovalent Vaccine
    Table 3. Major Manufacturers of Combination Vaccine
    Table 4. Global Varicella Attenuated Live Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 5. Global Varicella Attenuated Live Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 6. Global Varicella Attenuated Live Vaccine Sales by Region (2017-2022) & (K Doses)
    Table 7. Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2017-2022)
    Table 8. Global Varicella Attenuated Live Vaccine Sales by Region (2023-2028) & (K Doses)
    Table 9. Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2023-2028)
    Table 10. Global Varicella Attenuated Live Vaccine Revenue by Region (2017-2022) & (US$ Million)
    Table 11. Global Varicella Attenuated Live Vaccine Revenue Market Share by Region (2017-2022)
    Table 12. Global Varicella Attenuated Live Vaccine Revenue by Region (2023-2028) & (US$ Million)
    Table 13. Global Varicella Attenuated Live Vaccine Revenue Market Share by Region (2023-2028)
    Table 14. Global Varicella Attenuated Live Vaccine Sales by Manufacturers (2017-2022) & (K Doses)
    Table 15. Global Varicella Attenuated Live Vaccine Sales Share by Manufacturers (2017-2022)
    Table 16. Global Varicella Attenuated Live Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 17. Global Varicella Attenuated Live Vaccine Revenue Share by Manufacturers (2017-2022)
    Table 18. Varicella Attenuated Live Vaccine Price by Manufacturers (2017-2022) &(USD/Dose)
    Table 19. Global Varicella Attenuated Live Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 20. Global Varicella Attenuated Live Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Attenuated Live Vaccine as of 2021)
    Table 21. Varicella Attenuated Live Vaccine Manufacturing Base Distribution and Headquarters
    Table 22. Manufacturers Varicella Attenuated Live Vaccine Product Offered
    Table 23. Date of Manufacturers Enter into Varicella Attenuated Live Vaccine Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Varicella Attenuated Live Vaccine Sales by Type (2017-2022) & (K Doses)
    Table 26. Global Varicella Attenuated Live Vaccine Sales by Type (2023-2028) & (K Doses)
    Table 27. Global Varicella Attenuated Live Vaccine Sales Share by Type (2017-2022)
    Table 28. Global Varicella Attenuated Live Vaccine Sales Share by Type (2023-2028)
    Table 29. Global Varicella Attenuated Live Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 30. Global Varicella Attenuated Live Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 31. Global Varicella Attenuated Live Vaccine Revenue Share by Type (2017-2022)
    Table 32. Global Varicella Attenuated Live Vaccine Revenue Share by Type (2023-2028)
    Table 33. Varicella Attenuated Live Vaccine Price by Type (2017-2022) & (USD/Dose)
    Table 34. Global Varicella Attenuated Live Vaccine Price Forecast by Type (2023-2028) & (USD/Dose)
    Table 35. Global Varicella Attenuated Live Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 36. Global Varicella Attenuated Live Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 37. Global Varicella Attenuated Live Vaccine Sales Share by Application (2017-2022)
    Table 38. Global Varicella Attenuated Live Vaccine Sales Share by Application (2023-2028)
    Table 39. Global Varicella Attenuated Live Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 40. Global Varicella Attenuated Live Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 41. Global Varicella Attenuated Live Vaccine Revenue Share by Application (2017-2022)
    Table 42. Global Varicella Attenuated Live Vaccine Revenue Share by Application (2023-2028)
    Table 43. Varicella Attenuated Live Vaccine Price by Application (2017-2022) & (USD/Dose)
    Table 44. Global Varicella Attenuated Live Vaccine Price Forecast by Application (2023-2028) & (USD/Dose)
    Table 45. North America Varicella Attenuated Live Vaccine Sales by Type (2017-2022) & (K Doses)
    Table 46. North America Varicella Attenuated Live Vaccine Sales by Type (2023-2028) & (K Doses)
    Table 47. North America Varicella Attenuated Live Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 48. North America Varicella Attenuated Live Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 49. North America Varicella Attenuated Live Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 50. North America Varicella Attenuated Live Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 51. North America Varicella Attenuated Live Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 52. North America Varicella Attenuated Live Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 53. North America Varicella Attenuated Live Vaccine Sales by Country (2017-2022) & (K Doses)
    Table 54. North America Varicella Attenuated Live Vaccine Sales by Country (2023-2028) & (K Doses)
    Table 55. North America Varicella Attenuated Live Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 56. North America Varicella Attenuated Live Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 57. Europe Varicella Attenuated Live Vaccine Sales by Type (2017-2022) & (K Doses)
    Table 58. Europe Varicella Attenuated Live Vaccine Sales by Type (2023-2028) & (K Doses)
    Table 59. Europe Varicella Attenuated Live Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 60. Europe Varicella Attenuated Live Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 61. Europe Varicella Attenuated Live Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 62. Europe Varicella Attenuated Live Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 63. Europe Varicella Attenuated Live Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 64. Europe Varicella Attenuated Live Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 65. Europe Varicella Attenuated Live Vaccine Sales by Country (2017-2022) & (K Doses)
    Table 66. Europe Varicella Attenuated Live Vaccine Sales by Country (2023-2028) & (K Doses)
    Table 67. Europe Varicella Attenuated Live Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 68. Europe Varicella Attenuated Live Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 69. Asia Pacific Varicella Attenuated Live Vaccine Sales by Type (2017-2022) & (K Doses)
    Table 70. Asia Pacific Varicella Attenuated Live Vaccine Sales by Type (2023-2028) & (K Doses)
    Table 71. Asia Pacific Varicella Attenuated Live Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 72. Asia Pacific Varicella Attenuated Live Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 73. Asia Pacific Varicella Attenuated Live Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 74. Asia Pacific Varicella Attenuated Live Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 75. Asia Pacific Varicella Attenuated Live Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 76. Asia Pacific Varicella Attenuated Live Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 77. Asia Pacific Varicella Attenuated Live Vaccine Sales by Region (2017-2022) & (K Doses)
    Table 78. Asia Pacific Varicella Attenuated Live Vaccine Sales by Region (2023-2028) & (K Doses)
    Table 79. Asia Pacific Varicella Attenuated Live Vaccine Revenue by Region (2017-2022) & (US$ Million)
    Table 80. Asia Pacific Varicella Attenuated Live Vaccine Revenue by Region (2023-2028) & (US$ Million)
    Table 81. Latin America Varicella Attenuated Live Vaccine Sales by Type (2017-2022) & (K Doses)
    Table 82. Latin America Varicella Attenuated Live Vaccine Sales by Type (2023-2028) & (K Doses)
    Table 83. Latin America Varicella Attenuated Live Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 84. Latin America Varicella Attenuated Live Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 85. Latin America Varicella Attenuated Live Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 86. Latin America Varicella Attenuated Live Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 87. Latin America Varicella Attenuated Live Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 88. Latin America Varicella Attenuated Live Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 89. Latin America Varicella Attenuated Live Vaccine Sales by Country (2017-2022) & (K Doses)
    Table 90. Latin America Varicella Attenuated Live Vaccine Sales by Country (2023-2028) & (K Doses)
    Table 91. Latin America Varicella Attenuated Live Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 92. Latin America Varicella Attenuated Live Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 93. Middle East and Africa Varicella Attenuated Live Vaccine Sales by Type (2017-2022) & (K Doses)
    Table 94. Middle East and Africa Varicella Attenuated Live Vaccine Sales by Type (2023-2028) & (K Doses)
    Table 95. Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 96. Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 97. Middle East and Africa Varicella Attenuated Live Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 98. Middle East and Africa Varicella Attenuated Live Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 99. Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 100. Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 101. Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country (2017-2022) & (K Doses)
    Table 102. Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country (2023-2028) & (K Doses)
    Table 103. Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 104. Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 105. Merck Corporation Information
    Table 106. Merck Description and Major Businesses
    Table 107. Merck Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 108. Merck Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 109. Merck Recent Developments
    Table 110. BCHT Corporation Information
    Table 111. BCHT Description and Major Businesses
    Table 112. BCHT Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 113. BCHT Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 114. BCHT Recent Developments
    Table 115. Shanghai Institute Corporation Information
    Table 116. Shanghai Institute Description and Major Businesses
    Table 117. Shanghai Institute Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 118. Shanghai Institute Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 119. Shanghai Institute Recent Developments
    Table 120. GSK Corporation Information
    Table 121. GSK Description and Major Businesses
    Table 122. GSK Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 123. GSK Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 124. GSK Recent Developments
    Table 125. Keygen Corporation Information
    Table 126. Keygen Description and Major Businesses
    Table 127. Keygen Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 128. Keygen Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 129. Keygen Recent Developments
    Table 130. Green Cross Corporation Information
    Table 131. Green Cross Description and Major Businesses
    Table 132. Green Cross Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 133. Green Cross Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 134. Green Cross Recent Developments
    Table 135. Biken Corporation Information
    Table 136. Biken Description and Major Businesses
    Table 137. Biken Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 138. Biken Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 139. Biken Recent Developments
    Table 140. Shanghai Rongsheng Biotech Corporation Information
    Table 141. Shanghai Rongsheng Biotech Description and Major Businesses
    Table 142. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 143. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 144. Shanghai Rongsheng Biotech Recent Developments
    Table 145. Changchun Changsheng Life Sciences Limited Corporation Information
    Table 146. Changchun Changsheng Life Sciences Limited Description and Major Businesses
    Table 147. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 148. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 149. Changchun Changsheng Life Sciences Limited Recent Developments
    Table 150. Key Raw Materials Lists
    Table 151. Raw Materials Key Suppliers Lists
    Table 152. Varicella Attenuated Live Vaccine Distributors List
    Table 153. Varicella Attenuated Live Vaccine Customers List
    Table 154. Varicella Attenuated Live Vaccine Market Trends
    Table 155. Varicella Attenuated Live Vaccine Market Drivers
    Table 156. Varicella Attenuated Live Vaccine Market Challenges
    Table 157. Varicella Attenuated Live Vaccine Market Restraints
    Table 158. Research Programs/Design for This Report
    Table 159. Key Data Information from Secondary Sources
    Table 160. Key Data Information from Primary Sources
List of Figures
    Figure 1. Varicella Attenuated Live Vaccine Product Picture
    Figure 3. Global Varicella Attenuated Live Vaccine Market Share by Type in 2021 & 2028
    Figure 3. Monovalent Vaccine Product Picture
    Figure 4. Combination Vaccine Product Picture
    Figure 5. Global Varicella Attenuated Live Vaccine Market Share by Application in 2021 & 2028
    Figure 6. Kids Injection
    Figure 7. Adults Injection
    Figure 8. Varicella Attenuated Live Vaccine Report Years Considered
    Figure 9. Global Varicella Attenuated Live Vaccine Sales 2017-2028 (K Doses)
    Figure 10. Global Varicella Attenuated Live Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 11. Global Varicella Attenuated Live Vaccine Revenue 2017-2028 (US$ Million)
    Figure 12. Global Varicella Attenuated Live Vaccine Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 13. Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2017-2022)
    Figure 14. Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2023-2028)
    Figure 15. North America Varicella Attenuated Live Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 16. North America Varicella Attenuated Live Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 17. Europe Varicella Attenuated Live Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 18. Europe Varicella Attenuated Live Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 19. Asia-Pacific Varicella Attenuated Live Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 20. Asia-Pacific Varicella Attenuated Live Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 21. Latin America Varicella Attenuated Live Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 22. Latin America Varicella Attenuated Live Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 23. Middle East & Africa Varicella Attenuated Live Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 24. Middle East & Africa Varicella Attenuated Live Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 25. The Varicella Attenuated Live Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 26. The Top 5 and 10 Largest Manufacturers of Varicella Attenuated Live Vaccine in the World: Market Share by Varicella Attenuated Live Vaccine Revenue in 2021
    Figure 27. Global Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 28. Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2017-2028)
    Figure 29. Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2017-2028)
    Figure 30. Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2017-2028)
    Figure 31. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2017-2028)
    Figure 32. North America Varicella Attenuated Live Vaccine Sales Market Share by Type (2017-2028)
    Figure 33. North America Varicella Attenuated Live Vaccine Revenue Market Share by Type (2017-2028)
    Figure 34. North America Varicella Attenuated Live Vaccine Sales Market Share by Application (2017-2028)
    Figure 35. North America Varicella Attenuated Live Vaccine Revenue Market Share by Application (2017-2028)
    Figure 36. North America Varicella Attenuated Live Vaccine Sales Share by Country (2017-2028)
    Figure 37. North America Varicella Attenuated Live Vaccine Revenue Share by Country (2017-2028)
    Figure 38. U.S. Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 39. Canada Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 40. Europe Varicella Attenuated Live Vaccine Sales Market Share by Type (2017-2028)
    Figure 41. Europe Varicella Attenuated Live Vaccine Revenue Market Share by Type (2017-2028)
    Figure 42. Europe Varicella Attenuated Live Vaccine Sales Market Share by Application (2017-2028)
    Figure 43. Europe Varicella Attenuated Live Vaccine Revenue Market Share by Application (2017-2028)
    Figure 44. Europe Varicella Attenuated Live Vaccine Sales Share by Country (2017-2028)
    Figure 45. Europe Varicella Attenuated Live Vaccine Revenue Share by Country (2017-2028)
    Figure 46. Germany Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 47. France Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 48. U.K. Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 49. Italy Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 50. Russia Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 51. Asia Pacific Varicella Attenuated Live Vaccine Sales Market Share by Type (2017-2028)
    Figure 52. Asia Pacific Varicella Attenuated Live Vaccine Revenue Market Share by Type (2017-2028)
    Figure 53. Asia Pacific Varicella Attenuated Live Vaccine Sales Market Share by Application (2017-2028)
    Figure 54. Asia Pacific Varicella Attenuated Live Vaccine Revenue Market Share by Application (2017-2028)
    Figure 55. Asia Pacific Varicella Attenuated Live Vaccine Sales Share by Region (2017-2028)
    Figure 56. Asia Pacific Varicella Attenuated Live Vaccine Revenue Share by Region (2017-2028)
    Figure 57. China Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 58. Japan Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 59. South Korea Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 60. India Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 61. Australia Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 62. Taiwan Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 63. Indonesia Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 64. Thailand Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 65. Malaysia Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 66. Philippines Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 67. Latin America Varicella Attenuated Live Vaccine Sales Market Share by Type (2017-2028)
    Figure 68. Latin America Varicella Attenuated Live Vaccine Revenue Market Share by Type (2017-2028)
    Figure 69. Latin America Varicella Attenuated Live Vaccine Sales Market Share by Application (2017-2028)
    Figure 70. Latin America Varicella Attenuated Live Vaccine Revenue Market Share by Application (2017-2028)
    Figure 71. Latin America Varicella Attenuated Live Vaccine Sales Share by Country (2017-2028)
    Figure 72. Latin America Varicella Attenuated Live Vaccine Revenue Share by Country (2017-2028)
    Figure 73. Mexico Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 74. Brazil Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 75. Argentina Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 76. Middle East and Africa Varicella Attenuated Live Vaccine Sales Market Share by Type (2017-2028)
    Figure 77. Middle East and Africa Varicella Attenuated Live Vaccine Revenue Market Share by Type (2017-2028)
    Figure 78. Middle East and Africa Varicella Attenuated Live Vaccine Sales Market Share by Application (2017-2028)
    Figure 79. Middle East and Africa Varicella Attenuated Live Vaccine Revenue Market Share by Application (2017-2028)
    Figure 80. Middle East and Africa Varicella Attenuated Live Vaccine Sales Share by Country (2017-2028)
    Figure 81. Middle East and Africa Varicella Attenuated Live Vaccine Revenue Share by Country (2017-2028)
    Figure 82. Turkey Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 83. Saudi Arabia Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 84. U.A.E Varicella Attenuated Live Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 85. Varicella Attenuated Live Vaccine Value Chain
    Figure 86. Varicella Attenuated Live Vaccine Production Process
    Figure 87. Channels of Distribution
    Figure 88. Distributors Profiles
    Figure 89. Bottom-up and Top-down Approaches for This Report
    Figure 90. Data Triangulation
    Figure 91. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
Frequently Asked Questions
Varicella Attenuated Live Vaccine report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Varicella Attenuated Live Vaccine report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Varicella Attenuated Live Vaccine report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Cold Chain

Cold Chain market is segmented by players, region (country), by Type and by Application. Players, ... Read More

Dermatoscope

Dermatoscope market is segmented by Type and by Application. Players, stakeholders, and other par ... Read More